Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
NEW YORK, Nov. 03, 2016 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, November 7, 2016 at 8:30am ET to discuss results for the third quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Third Quarter 2016 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Vice President- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
